Zhitong Finance APP Newsblockchainvrgames, Baili Tianheng (688506blockchainvrgames.SH) announced that the first phase III clinical trial of the company's independently developed innovative biopharmaceutical injection BL-M07D1 (HER2-ADC) single agent for locally advanced or metastatic HER2-positive breast cancer has recently completed the first subject enrolled. BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors.
